ERGO (Entia Biosciences) Notes Receivable: $0.00 Mil (As of Dec. 2016)


What is Entia Biosciences Notes Receivable?

Entia Biosciences ERGO Notes Receivable is $0.00 Mil as of Dec. 2016.

Entia Biosciences's Notes Receivable for the quarter that ended in Dec. 2016 was $0.00 Mil.

Entia Biosciences Notes Receivable Related Terms

Entia Biosciences Notes Receivable Historical Data

* Premium members only.

The historical data trend for Entia Biosciences's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entia Biosciences Notes Receivable Chart

Entia Biosciences Annual Data
Trend Jul07 Jul08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Entia Biosciences Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Entia Biosciences Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Entia Biosciences (ERGO) has a Notes Receivable of $0.00 Mil as of Dec. 2016. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Entia Biosciences and its competitors.
Is Entia Biosciences' Notes Receivable too high?
Entia Biosciences' current Notes Receivable is $0.00 Mil.
How does Entia Biosciences' Notes Receivable compare to OBMP and NSPX?
Entia Biosciences' Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Entia Biosciences and its competitors. Entia Biosciences's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entia Biosciences stock overvalued right now?
Entia Biosciences (ERGO) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Entia Biosciences (ERGO), the current Notes Receivable is $0.00 Mil as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entia Biosciences Business Description

Address 13565 South West Tualatin-Sherwood Road, Suite 800, Sherwood, OR, USA, 97140
Entia Biosciences Inc operates as a biotechnology company, is engaged in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products, principally in the United States of America. It market nutraceutical products under the name GROH and SANO directly to the consumers online. It currently offers natural organic nutraceutical mushroom dietary supplement products, ImmuSANO, GlucoSANO, and GROH, which has been designed to nutritionally support hair follicles and nail beds. It derives its revenue from the sale of its GROH line and mushroom-based nutraceutical dietary supplement products and functional ingredients.